Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Phase I dendritic cell p53 peptide vaccine for head and neck cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2014

Schuler Patrick J, Harasymczuk Malgorzata, Visus Carmen, Deleo Albert, Trivedi Sumita, Lei Yu, Argiris Athanassios, Gooding William, Butterfield Lisa H, Whiteside Theresa L, Ferris Robert L

Abstract excerpt

BACKGROUND: p53 accumulation in head and neck squamous cell carcinoma (HNSCC) cells creates a targetable tumor antigen. Adjuvant dendritic cell (DC)-based vaccination against p53 was tested in a phase I clinical trial. EXPERIMENTAL METHODS: Monocyte-derived DC from 16 patients were loaded with two modified HLA-class I p53 peptides (Arm 1), additional Th tetanus toxoid peptide (Arm 2), or additional Th wild-type...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Vaccines
Share to Head and Neck Neoplasms

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Lymphocytes, Tumor-Infiltrating

Share to Squamous Cell Carcinoma of Head and Neck

Share to T-Lymphocytes, Cytotoxic

Share to T-Lymphocytes, Regulatory

Share to Vaccination

Source

Open in PubMed Open full text

Identifiers

PMID: 24583792
DOI: 10.1158/1078-0432.CCR-13-2617
PMCID: PMC4017234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Phase I dendritic cell p53 peptide vaccine for head and neck cancer.PMID 24583792Read ↗

Personalized cancer vaccination in head and neck cancer.Semantic proximity Read ↗

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.Semantic proximity Read ↗

Refining Dendritic Cell-Based Cancer Vaccines: Subset Targeting, Translational Barriers, and Emerging StrategiesSemantic proximity Read ↗

Generation of T cells specific for the wild-type sequence p53(264-272) peptide in cancer patients: implications for immunoselection of epitope loss variants.Semantic proximity Read ↗

Langerhans-type dendritic cells electroporated with TRP-2 mRNA stimulate cellular immunity against melanoma: Results of a phase I vaccine trialSemantic proximity Read ↗

Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of GlioblastomaSemantic proximity Read ↗

Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response.Semantic proximity Read ↗

Human Papilloma Virus Specific Immunogenicity and Dysfunction of CD8+ T Cells in Head and Neck Cancer.Semantic proximity Read ↗

Cd73-LNPs promotes antitumor T-cell immunity via amplifying Tlr3-mediated immunostimulatory dendritic cell activationSemantic proximity Read ↗

Enhanced Cytotoxic CD8 T Cell Priming Using Dendritic Cell-Expressing Human Papillomavirus-16 E6/E7-p16INK4 Fusion Protein with Sequenced Anti-Programmed Death-1.Semantic proximity Read ↗

Dendritic Cell Strategies for Eliciting Mutation-Derived Tumor Antigen Responses in Patients.Semantic proximity Read ↗

Optimized mobilization of MHC class I- and II- restricted immunity by dendritic cell vaccine potentiates cancer therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.